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Abstract
A Novel Plant Cell Culture Platform for Semicontinuous Production of 
Recombinant Proteins: Butyrylcholinesterase as a Case Study
Jasmine M. Corbin1, Bryce I. Hashimoto1, Kalimuthu Karuppanan1, Raymond L. Rodriguez2,
Somen Nandi2, Brian A. Roberts3, Amy R. Noe3 and Karen A. McDonald1
1 Chemical Engineering and Materials Science, University of California, Davis, CA; 2 Molecular and Cellular Biology, University of California, Davis, CA;  3 Leidos, Inc, Frederick, MD
Background
In this poster we describe a novel biomanufacturing production
platform that utilizes transgenic rice cell suspension cultures
for efficient semicontinuous cell culture production of
recombinant proteins. This platform offers a number of
advantages over traditional methods for production of
recombinant therapeutic proteins that use E. coli, yeast or
mammalian cell cultures, while still retaining the ability to meet
cGMP regulatory requirements under well-controlled,
reproducible production conditions. Results are presented for
semicontinuous production of butyrylcholinesterase, a
bioscavenger for organophosphorus nerve agents such as
sarin, using metabolically regulated transgenic rice cell
cultures in a 5 L bioreactor.
Traditional methods for production of biologics use genetically
modified E. coli, yeast, insect or mammalian cell cultures in
bioreactor systems. For applications where a human
therapeutic protein (monoclonal antibodies, vaccines,
bioscavengers, replacement biologics) produced under strict
cGMP conditions is required, plant cell cultures offer a number
of advantages over currently used bioreactor-based systems:
• Low risk of contamination by mammalian viruses, blood-
borne pathogens, prions or bacterial endotoxins or
mycoplasma
• Ability to perform complex glycosylation
• Ease of culturing compared with other higher eukaryotic
hosts
• Ability to grow in simple, low cost, chemically defined and
animal component-free medium
• Established regulatory pathway for plant-based recombinant
biologics for use as a human therapeutic
In the presented work, we focus on butyrylcholinesterase
(BuChE) as a case study. BuChE is a tetrameric human
enzyme that can act as a bioscavenger against
organophosphorus nerve agents (Figure 1). Because of the
high cost and limited availability of BuChE from human blood
plasma, there is a need for a low cost, scalable recombinant
platform for BuChE production.
Expression of the BuChE gene is controlled by the rice alpha
amylase 3D promoter2, which is activated by switching the rice
from a sucrose-rich growth medium to a sucrose-free induction
medium. This allows for a cyclical or semi-continuous culture
operation that alternates between phases of cell growth (sugar-
rich) and expression (sugar-free). Gravity sedimentation within
the bioreactor can be used to separate the plant cell
aggregates from the liquid phase, and the product collected
can be purified either using a batch downstream strategy or fed
to a continuous downstream process.
Conclusions
Results: Semicontinuous Bioreactor Operation
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• Confirmed multiple stable transgenic cell lines capable of
producing BuChE in a suspension culture.
• Successfully produced mg quantities of functional BuChE semi-
continuously in a lab scale bioreactor.
• Induction #2 shows active BuChE present in the media at levels
comparable to active cell-associated BuChE in Induction #1.
• Preliminary data indicate the production of tetrameric BuChE.
Figure 6: Kinetic data from semicontinuous 
production of BuChE in transgenic rice cell 
cultures under controlled conditions of 
temperature (27°C), agitation (75 rpm), and 
dissolved oxygen (40% of saturation with air). 
in a 5 L bioreactor.
Figure 6a: Cell growth and oxygen uptake
rate (OUR) kinetics.
Figure 6b: BuChE production and sugar
consumption kinetics. Active BuChE
concentration is determined by a modified
Ellman activity assay3.
Figure 7: Western blotting of rice cell 
culture-produced BuChE.
Figure 7a: Western blot under reducing
conditions of cell-associated samples
from before and after medium
exchanges. Each lane contains 20 µL of
crude cell extract, obtained by grinding
cells 1:1 in cold extraction buffer using
a tissue homogenizer. Maximum
BuChE expression occurs on day 5
after induction.
Figure 7b: Western blot under native
conditions of 52 mU (~200ng) active
BuChE from an intracellular sample
from the first bioreactor expression
phase (Induction #1). Tetrameric
BuChE (~340 kDa) is observed.
Figure 1: The tetrametic 
form of BuChE is 340 kDa1.
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Materials and Methods












2 Equine BuChE Control
• Optimization of bioreactor operating parameters, such as inoculation
density, aggregate size distribution, dissolved oxygen, temperature, pH,
and timing of induction in order to maximize culture health and
volumetric productivity of functional BuChE.
• Evaluation of long-term (> 1 month) semicontinuous BuChE production.
• Purification and biochemical characterization of rice cell culture-








11.5 ± 0.1 µg/g FW 178.4 ± 23.6 µg/g FW
0.306 ± 0.003 mg/L culture 8.4 ± 1.1 mg/L culture
Max Volumetric





% base pairs different 25.3%
% codons different 64.1%
Codon Adaptation Index 0.68 0.83
Nc (effective # of codons) 47 41
Overall GC Content (%) 40.2 51.4
%GC in 1st place
%GC in 2nd place











Maximum Specific Growth 
Rate (µmax)
0.17 ± 0.01 day-1 0.16 ± 0.02 day-1
Doubling Time (τD) 4.0 ± 0.2 days 4.4 ± 0.7 days
Figure 7a
# Contents
1 Day 0—immediately before Induction #1
2 Day 0—immediately after Induction #1
3 Day 2 of Induction #1
4 Day 4 of Induction #1
5 Day 5—immediately before Growth #2
6 Day 5—immediately after Growth #2
7 Day 7 of Growth #2
8 Day 9 of Growth #2
9 Equine BuChE Control (900 ng)
Figure 2: Schematic of the gene construct and codon 
optimization data. 
Figure 3: BuChE expression levels from the top 20 highest 
expressing transformation events of 300 total events screened.
Figure 4 (above): Schematic of the semi-continuous culture operation method.
Figure 5 (right): Transgenic rice cell culture grown in a 5 L bioreactor.
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